HighTower Advisors
RETA

HighTower Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

HighTower Advisors’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-47,574
Closed -$4.85M – 3808
2023
Q2 		$4.85M Sell
47,574
-1,404
-3% -$133K 0.01% 922
2023
Q1 		$4.45M Sell
48,978
-3,417
-7% -$201K 0.01% 913
2022
Q4 		$1.99M Sell
52,395
-3,755
-7% -$129K ﹤0.01% 1292
2022
Q3 		$1.41M Buy
56,150
+135
+0.2% +$3.74K ﹤0.01% 1427
2022
Q2 		$1.71M Buy
56,015
+1,500
+3% +$44.8K ﹤0.01% 1349
2022
Q1 		$1.79M Sell
54,515
-308
-0.6% -$9.14K ﹤0.01% 1444
2021
Q4 		$1.45M Sell
54,823
-4,267
-7% -$330K ﹤0.01% 1559
2021
Q3 		$5.94M Sell
59,090
-10,170
-15% -$1.19M 0.02% 743
2021
Q2 		$9.8M Buy
69,260
+10,302
+17% +$1.16M 0.03% 525
2021
Q1 		$5.88M Sell
58,958
-35
-0.1% -$4.08K 0.02% 686
2020
Q4 		$7.3M Buy
58,993
+4,155
+8% +$546K 0.03% 467
2020
Q3 		$5.34M Buy
+54,838
New +$6.85M 0.03% 534

Other funds holding RETA

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HighTower Advisors's RETA Position: Q3 2023 in Review

HighTower Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 47,574 shares — an estimated $4.85M sold.

HighTower Advisors first reported a position in RETA in Q3 2020 and held it in 12 quarters. The position peaked at $9.8M in Q2 2021. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

  • HighTower Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
  • HighTower Advisors sold 47,574 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $4.85M.
  • HighTower Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2020 and held it in 12 quarters.
  • HighTower Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $9.8M in Q2 2021.
  • 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on HighTower Advisors's 13F filing for Q3 2023, filed 8 Nov 2023.